Skip to main content

Table 5 PSA results (ref. Standard care)

From: Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study

Strategy

Cost

Δ Cost

QALY

Δ QALY

ICER

Standard Care

33371.7

 

0.7677

  

Dexamethasone

33555.6

183.9

0.8028

0.0352

5229.1

Remedesivir

32388.4

-983.3

0.7736

0.0059

Dominant

Rem + Dex

32572.2

-799.4

0.8087

0.0411

Dominant